- Recommendation ID
- NG122/1
- Question
What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell lung cancer following multimodality treatment including surgery?
- Any explanatory notes
(if applicable)
Source guidance details
- Comes from guidance
- Lung cancer: diagnosis and management
- Number
- NG122
- Date issued
- March 2019
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 28/03/2019 |